Andrew Hirsch

Andrew Hirsch, MBA joined C4 Therapeutics in September 2020 as our President, Chief Executive Officer, and a member of our Board of Directors. Previously, Andrew was Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals, Inc. Andrew has more than 25 years of experience in a range of strategic and operating roles in the biotechnology sector, previously serving as President and Chief Executive Officer of BIND Therapeutics, Inc. Prior to being named President and Chief Executive Officer, Andrew held several other leadership positions at BIND, including Chief Operating Officer and Chief Financial Officer. Before joining BIND, Andrew was Chief Financial Officer at Avila Therapeutics, Inc. from June 2011 until its acquisition by Celgene Corporation. From 2002 to 2011, Andrew held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team. Andrew has served on the Board of Directors of Editas Medicine, Inc. since May 2017. Additionally, he has served on the Board of Directors of Akamis Bio, a privately held clinical-stage oncology company where he serves as chair of the audit committee and a member of the compensation committee, since August 2025. Andrew holds an MBA from the Tuck School at Dartmouth College and a B.A. in economics from the University of Pennsylvania.